Twice-Daily NPH or Mixture Insulins Versus Triple Therapy: Apples Versus Oranges
Response to Poulsen et al.
- From the Clinical Trials Unit, Charles R. Drew University, Los Angeles, California
- Address correspondence to Dr. Mayer B. Davidson, MD, Director, Clinical Trials Unit, Charles R. Drew University, 1731 East 120th St., Los Angeles, CA 90059. E-mail: madavids{at}cdrewu.edu
Poulsen et al. (1) recently demonstrated that triple therapy (metformin, rosiglitazone, and preprandial insulin aspart) lowered HbA1c levels much better than twice-daily NPH or MIX insulin in type 2 diabetic patients. They then claim that the reason for this improvement, compared with the patients treated with insulin alone, is the superiority of specifically treating the three pathophysiological components of type 2 …
